A method for treating a purified intermediate of an antibody molecule

By diluting the intermediates of antibody molecules, using buffer treatment of salts and amino acids, the stability of antibody molecules in the freeze-thawing process is improved, and the problem of unstable freeze-thawing intermediates of antibody molecules purification is solved, ensuring high purity and process robustness.

CN114380916BActive Publication Date: 2024-12-03ALTRUIST BIOLOGICS (SUZHOU) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202111132993.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2020-09-27
Filing Date
2021-09-27
Publication Date
2024-12-03
Estimated Expiration
2041-09-27

AI Technical Summary

Technical Problem

The intermediate for purification of antibody molecules is unstable during freeze-thawing, resulting in a decrease in the quality of antibody drugs, affecting the subsequent purification process and product quality.

Method used

Use a buffer containing salt and/or amino acids to dilute the antibody molecules to purify the intermediate, adjust the pH to 5.5-6.0, the dilution ratio is more than 1, and the final concentration is 80-100mM. The salts used can be sodium chloride, potassium chloride or Sodium sulfate, amino acids may be glycine or histidine. After dilution, the sample is filtered and optionally stored at -80°C for virus removal filtering.

Benefits of technology

The freeze-thaw stability of the antibody molecular purification intermediate is improved, so that its purity is maintained above 99.0% during the freeze-thaw process, reducing the cost of the downstream purification process and increasing the flexibility of the process.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114380916B_ABST
    Figure CN114380916B_ABST
Patent Text Reader

Abstract

The present invention discloses a method for treating a purified intermediate of an antibody molecule. The method comprises: diluting the purified intermediate with a buffer containing salt and / or amino acids, adjusting the pH to 5.5-6.0, and obtaining a diluted sample. The present invention improves the short-term and long-term stability of the diluted sample by adding salt and / or amino acids to the cationic dilution buffer and adjusting the pH of the final diluted sample, so that the antibody drug molecule still maintains a high purity after being frozen and thawed 5 times and frozen for 150 days.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of antibody purification, and in particular to a method for treating a purified intermediate of an antibody molecule. Background Art

[0002] The purification process of antibody drugs is relatively complicated. It is necessary to combine multiple separation methods and design a reasonable purification process to efficiently obtain high-quality antibody products. The typical purification process of antibody drugs includes capture (such as affinity chromatography or ion exchange chromatography), intermediate purification (such as low virus inactivation, adsorption deep filtration, ion exchange chromatography, hydrophobic chromatography, etc.), fine purification (ion exchange chromatography, hydrophobic chromatography, etc.), virus removal filtration, ultrafiltration concentration, liquid exchange, stock solution preparation and other unit operations. Liquid freezing and freeze drying are commonly used methods to maintain the stability of biomacromolecules (L'ubica Krausková, Jitka Procházková, Martina ková. Suppression of Protein Inactivation During Freezing by Minimizing pH Changes Using Ionic Cryoprotectants. Int J Pharm, 2016, 509 (1-2): 41-49). In the process of antibody drug process development and actual production, it is often necessary to place the intermediates of the purification process and the final stock solution and finished product at low temperature for short-term or long-term freezing to maintain the stability of the sample properties. However, in some cases, the liquid freezing and freeze-drying process of biomacromolecules will lead to partial degradation, aggregation and loss of activity of biomacromolecules. The freezing and thawing process will cause the pH value of the microenvironment in which the antibody molecules are located to change dramatically, thereby changing the higher-order structure of the antibody molecules (Lu Liu, Latoya Jones Braun, Wei Wang et al. Freezing-Induced Perturbation of Tertiary Structure of a Monoclonal Antibody. J Pharm Sci, 2014, 103 (7): 1979-1986), producing insoluble particles and soluble polymers (Hauptmann A, ek K, Kuzman D, et al. Impact of Buffer, Protein Concentration and Sucrose Addition on the Aggregation and Particle Formation During Freezing and Thawing. Pharm Res, 2018, 35(5): 101), which significantly affects the quality of antibody drugs (such as purity, turbidity, etc.), and the quality tends to deteriorate with the increase of freeze-thaw cycles.

[0003] The mechanism of protein freeze-thaw instability is relatively complex and has not yet been fully revealed. There are also many influencing factors, mainly including: the concentration of the protein solution, pH, salt concentration and type, the final temperature of freezing and thawing, heating and cooling rates, the presence or absence of cryoprotectant components, the content of cryoprotectant, etc. It has been reported that when the protein solution contains sodium phosphate, the pH change during the freezing process is more dramatic (KA Pikal-Cleland, N Rodríguez-Hornedo, GL Amidon, etc. Protein Denaturation During Freezing and Thawing in Phosphate Buffer Systems: Monomeric and Tetrameric Beta-Galactosidase. Arch Biochem Biophys, 2000, 384 (2): 398-406), while the pH change of the protein solution during the cooling process of potassium phosphate solution is small (less than or equal to 0.3 pH unit). The stability of some proteins in low temperature or freeze-dried state can be improved by adding ionic cryoprotectants, polyols and sugar substances, freeze-drying protective agents, and selecting appropriate buffer pH and salt. Antibody drug molecule preparations generally take the above factors into consideration. The preparation ingredients generally contain suitable salts, cryoprotectants (such as sorbitol or sucrose or mannose, etc.), surfactants (Tween-80 or Tween-20) and other ingredients are added. The pH of the preparation is generally within the pH range of its optimal stability, so there are few reports of freeze-thaw instability in antibody preparations. The freeze-thaw stability of intermediates in the purification process of antibody molecules is also rarely concerned. These intermediates generally do not contain components similar to those of antibody drug preparations. Therefore, compared with the stock solution and finished product (antibody molecules are in the preparation buffer system), the probability of freeze-thaw instability of large-volume samples in the purified intermediates is greater. Freeze-thaw instability in the purification intermediates of a certain step of the antibody molecule will bring many adverse effects, such as adverse effects on the process control, product quality and process robustness of the subsequent purification process connected with it, and will also interfere with the effect of virus removal verification and increase the cost of downstream purification. In the future, with the integration of upstream continuous processes and downstream purification processes, there will be a step of freezing downstream purification intermediate samples in actual production (CHMP assessment report, EMA / CHMP / 258608 / 2014). Therefore, it will become particularly important to solve the problem of freeze-thaw instability of purified intermediates. Summary of the invention

[0004] The technical problem to be solved by the present invention is to provide a method for treating an antibody molecule purification intermediate in view of the defect of instability of antibody molecules during freeze-thaw process in the prior art. The treatment method can improve the freeze-thaw stability of antibody molecule purification intermediates, so that the purity of antibody molecules remains basically unchanged during freeze-thaw process.

[0005] The present invention mainly solves the above technical problems through the following technical solutions.

[0006] The first aspect of the present invention provides a method for treating a purified intermediate of an antibody molecule, comprising:

[0007] The purified intermediate is diluted with a buffer containing salt and / or amino acid, and the pH is adjusted to 5.5-6.0 to obtain a diluted sample; wherein:

[0008] The dilution multiple is greater than 1, and the final concentration of the salt and / or amino acid is 80-100 mM;

[0009] The purified intermediate is a cationic collection solution obtained by eluting the antibody molecule;

[0010] The buffer salt of the buffer is the same as that of the buffer used for elution.

[0011] The salt may be a salt commonly used in the buffer used in the purification process, preferably one or more of sodium chloride, potassium chloride and sodium sulfate; for example, sodium chloride, potassium chloride or sodium sulfate.

[0012] The amino acids described in the present invention may be conventional ones in the art, preferably glycine and / or histidine.

[0013] The buffer salt described in the present invention can be conventional in the art, preferably acetic acid-sodium acetate, citric acid-sodium citrate or phosphate; more preferably, the acetic acid-sodium acetate buffer used for the elution does not contain salt and amino acids, thereby ensuring the purity of the eluted collection solution and the yield of the antibody molecules, and making the parameter range easy to control when the subsequent process is scaled up.

[0014] The pH of the cation collection solution is preferably 5.0-5.2.

[0015] In a specific embodiment of the present invention, the buffer used for the dilution comprises:

[0016] 20-25 mM acetic acid-sodium acetate and 200 mM NaCl; or, 40 mM acetic acid-sodium acetate and 200 mM arginine.

[0017] Preferably, after the dilution, the concentration of the acetic acid-sodium acetate in the sample is 160-200 mM, and the concentration of the NaCl or the arginine is 100 mM.

[0018] Preferably, the pH of the diluted sample is adjusted to 5.5; preferably, Tris, sodium acetate and / or arginine hydrochloride are used to adjust the pH.

[0019] The concentration of the antibody molecules in the diluted sample of the present invention is preferably below 8 g / L.

[0020] The processing method described in the present invention also includes the following steps:

[0021] (i) filtering the diluted sample and optionally storing it at -80°C;

[0022] (ii) Thawing and filtering in a 26°C water bath to remove viruses;

[0023] The filtration in steps (i) and (ii) preferably uses a 0.22 micron filter.

[0024] The pH of the buffer used for elution in the present invention is preferably 5.0-5.4; the elution is preferably isocratic elution or gradient elution; more preferably gradient elution.

[0025] The treatment method of the present invention is applicable to conventional antibody molecules in the art, preferably bispecific antibodies, more preferably OX40 / PDL1 bispecific antibodies; the OX40 / PDL1 bispecific antibody preferably comprises polypeptide chain 1: VH-CH1-CH2-CH3-linker-VHH, and polypeptide chain 2: VL-CL.

[0026] The second aspect of the present invention provides a use of a salt or an amino acid in preparing a buffer for diluting a purified intermediate, wherein the purified intermediate is a cationic collection solution obtained by eluting the antibody molecule.

[0027] Wherein, the final concentration of the salt or the amino acid in the diluted sample is preferably 80-100 mM.

[0028] The salt is preferably one or more of sodium chloride, potassium chloride and sodium sulfate, for example: sodium chloride, potassium chloride or sodium sulfate.

[0029] The amino acid is preferably glycine and / or histidine, such as glycine or histidine.

[0030] For the preferred definitions of the antibody molecules described in the second aspect, please refer to the definitions of the relevant terms in the first aspect of the present invention.

[0031] On the basis of being in accordance with the common sense in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain the preferred embodiments of the present invention.

[0032] The reagents and raw materials used in the present invention are commercially available.

[0033] The positive and progressive effects of the present invention are:

[0034] A method for improving freeze-thaw stability of antibody molecule purification intermediates of the present invention

[0035] 1. The cationic collection solution of antibody molecules can be frozen and thawed 1-5 times at -80℃ to 26℃, and the purity can be maintained above 99.0%;

[0036] 2. The virus removal filtration verification was performed using the cationic collection liquid after the above treatment. The loading capacity remained basically unchanged, and the purity of the virus removal filtration collection liquid was maintained at more than 99.0%; the improvement of purity by the process of the present invention indirectly proved that the loading capacity of the filtration rate would not have a negative impact;

[0037] 3. The purity of cation collection solutions of different scales and batches is comparable, and the cation and subsequent processes are robust and easy to control;

[0038] 4. The treated cation collection liquid can be frozen at low temperature, which increases the flexibility of the downstream cation exchange chromatography process and its subsequent virus removal filtration process. BRIEF DESCRIPTION OF THE DRAWINGS

[0039] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0040] Figure 1 The purity of samples with different dilutions varies with the number of freeze-thaw cycles. DETAILED DESCRIPTION

[0041] The following is a preferred embodiment of the present invention, and the protection of the present invention is not limited to the following preferred embodiments. It should be pointed out that for those skilled in the art, a number of variations and improvements made on the basis of this invention conception all belong to the protection scope of the present invention. The raw materials used in the examples can all be obtained through commercial channels. The SEC (monomer purity) detection involved in the examples is detected by molecular exclusion high performance liquid chromatography. All reagents involved in the examples are commercially available pharmaceutical grade or analytically pure raw materials. The experimental methods for which specific conditions are not specified in the examples are selected according to conventional methods and conditions, or according to the product instructions.

[0042] The following embodiments involve different cation collecting solutions and dilutions thereof. To distinguish different cation collecting solutions and dilutions of different cation collecting solutions, Arabic numerals are used after the terms, for example: cation collecting solution 1, cation collecting solution 2. The numbers have no practical meaning. The terms before the same number correspond to each other, such as the dilution of "cation collecting solution 1" is "dilution 1 of cation collecting solution".

[0043] The OX40 / PDL1 bispecific antibody (IBI327) mentioned below is disclosed in WO2020151761.

[0044] Example 1 Dilution Processing of OX40 / PDL1 Bispecific Antibody Cationic Collection Solution 1

[0045] (1) Purification of OX40 / PDL1 bispecific antibody by cation exchange chromatography

[0046] Using GE's Capto S Impact filler, three copies of OX40 / PDL1 bispecific antibody were taken, the sample loading was 40-50 g / L, the balancing solution and elution A solution were 150 mM acetic acid-sodium acetate, pH 5.0; the elution B solution was 500 mM acetic acid-sodium acetate, pH 5.2; after the loading was completed, 3 column volumes were balanced with the balancing solution, and then eluted with a linear gradient of 20-80% B for 10 column volumes to obtain cation collection solution 1 (concentration 14.7 g / L), cation collection solution 2 (concentration 13.9 g / L), and cation collection solution 3 (concentration 14.2 g / L). The above cation collection solutions were sampled and frozen in a -80°C refrigerator, and the remaining samples were temporarily stored at room temperature or 4°C.

[0047] (2) The cationic collection solution of the above-mentioned OX40 / PDL1 bispecific antibody was diluted with dilution buffer (20 mM acetic acid-sodium acetate, 200 mM NaCl, pH 5.3), and the concentration of NaCl in the final dilution solution ranged from 80 to 100 mM. The solution was dispensed into 1.5 to 50 ml centrifuge tubes or 200 to 2000 ml PETG bottles and placed at -80°C for 3 to 90 days. The number of freeze-thaw cycles at -80°C and room temperature was 1 to 3.

[0048] (3) The samples after freezing and thawing were sent for purity testing, and the purity data are shown in Table 1. When the samples were frozen and thawed once from -80°C to room temperature, the purity of the cation collection solution and the diluted treatment solution of the cation collection solution almost did not change. However, when the samples were frozen and thawed three times from -80°C to room temperature, the purity of the cation collection solution and the diluted treatment solution of the cation collection solution decreased significantly, and the purity of the cation collection solution decreased more significantly. The sample with a high NaCl content in the diluted treatment solution of the cation collection solution (cation collection solution diluted treatment solution 1) had a relatively small decrease in purity.

[0049] Table 1 Comparison of the purity of the cation collection solution before and after dilution treatment with different freeze-thaw times

[0050]

[0051]

[0052] Example 2 Dilution Processing of OX40 / PDL1 Bispecific Antibody Cationic Collection Solution 2

[0053] (1) Purification of OX40 / PDL1 bispecific antibody by cation exchange chromatography

[0054] GE Capto S Impact filler was used, the sample loading was 50-60 g / L, the balance solution was 150 mM acetic acid-sodium acetate, pH 5.0; the elution solution B was 325 mM acetic acid-sodium acetate, pH 5.0; after the sample was loaded, the balance solution was used to balance 3 column volumes, and then eluted isocratically for 5 column volumes. Cationic collection solutions 4 and 5 were obtained, and samples were taken and frozen in a -80 ° C refrigerator, and the remaining samples were temporarily stored at room temperature or 4 ° C. The difference between cationic collection solutions 4 and 5 is that the purified antibodies came from different batches and used different chromatography columns XK26 (column volume 114.1 mL) and XK16 (column volume 48.9 mL).

[0055] (2) The cationic collection solution of the above-mentioned OX40 / PDL1 bispecific antibody was diluted with dilution buffer. The dilution buffer of cationic collection solution 4 was 300 mM acetic acid-sodium acetate, pH 5.0, and the dilution buffer of cationic collection solution 5 was 325 mM acetic acid-sodium acetate, pH 5.0. The concentration of OX40 / PDL1 bispecific antibody in the dilution solution of the cationic collection solution was controlled to be lower than 8.0 g / L. The solution was placed at -80°C and frozen and thawed at -80°C and room temperature once.

[0056] (3) The samples were sent for purity testing after freezing and thawing. The purity data are shown in Table 2 below. The purity of the cation collection solution and the dilution solution of the cation collection solution decreased slightly after a short-term freeze-thaw cycle of 16 h. As the freezing time increased, the purity tended to decrease gradually.

[0057] Table 2 Comparison of the purity of the cation collection solution before and after dilution treatment with different freeze-thaw times

[0058]

[0059] Example 3 Dilution Processing of OX40 / PDL1 Bispecific Antibody Cationic Collection Solution 3

[0060] (1) OX40 / PDL1 cation exchange chromatography purification: GE Capto S Impact filler was used, with a sample loading of 50-60 g / L. The equilibration solution and elution solution A were 150 mM acetic acid-sodium acetate, pH 5.0; the elution solution B was 500 mM acetic acid-sodium acetate, pH 5.2. After the sample was loaded, the equilibration solution was used to equilibrate for 3 column volumes, and then a linear gradient of 20-80% B was used for elution for 10 column volumes. The cation collection solution was sampled and frozen in a -80°C refrigerator, and the remaining sample was temporarily stored at room temperature or 4°C.

[0061] (2) The cation collection solution of the above-mentioned OX40 / PDL1 bispecific antibody (pH 5.1, concentration 16.5 g / L, conductivity 12.8 mS / cm) was subjected to the following four different dilution treatments: (a) the cation collection solution was diluted about 1-fold with dilution buffer 1 (50 mM acetic acid-sodium acetate, pH 5.43) to adjust the pH to 5.1; (b) the cation collection solution was diluted 1-fold with dilution buffer 2 (25 mM acetic acid-sodium acetate, 200 mM NaCl, pH 5.1) to adjust the pH to 5.1; (c) the cation collection solution was diluted 1-fold with dilution buffer 3 (25 mM acetic acid-sodium acetate, 200 mM NaCl, pH 5.5) to adjust the pH to 5.5; (d) the cation collection solution was diluted 1-fold with dilution buffer 4 (40 mM acetic acid-sodium acetate, 200 mM arginine, pH 5.5) Dilute the cationic collection solution by 1 time and adjust the pH to 5.5; the diluted samples are divided into 250ml PETG bottles and stored in a -80℃ refrigerator. Take them out after a period of time and thaw them in a 26℃ water bath. Sample 1ml and filter it with a 0.22 micron filter membrane for purity testing. The remaining samples are frozen in a -80℃ refrigerator. The 1st to 4th samplings are frozen at -80℃ for 6h, 12h, 36h and 48h respectively, and the 5th sampling is frozen at -80℃ for ~150 days.

[0062] (3) Results: The purity of different diluted samples changes with the number of freeze-thaw cycles. Figure 1 The detailed information of the cation collection solution dilution samples is shown in Table 3.

[0063] Table 3 Detailed information of the dilution sample of the cation collection solution

[0064]

[0065] Dilution sample 1 reduces the concentration and conductivity of the cation collection solution. After two short-term freeze-thaw cycles, the purity decreases slightly. However, with the increase in the number of freeze-thaw cycles and the extension of the -80℃ freezing time, the purity decreases significantly. Dilution sample 2 increases the concentration of NaCl in the cation collection solution by 100mM. After four short-term freeze-thaw cycles, the purity decreases slightly and remains above 99%. However, after 150 days of long-term freeze-thaw, the purity decreases significantly. Compared with dilution sample 2, the difference between dilution sample 3 and dilution sample 2 is that the pH of dilution sample 3 is higher than that of dilution sample 2, resulting in dilution sample 3 still maintaining good stability under 150 days of long-term freeze-thaw, and the purity decreases slightly, and the purity remains at 99.3%. The pH of dilution sample 4 is 5.5, and 100mM arginine is added. Like dilution sample 3, it still maintains good stability under 150 days of long-term freeze-thaw, and the purity decreases slightly, and the purity remains at 99.3%.

[0066] Example 4 Virus removal filtration membrane capacity test of OX40 / PDL1 bispecific antibody

[0067] The samples diluted with the cation collection liquid were selected for the virus removal filter membrane load test. The virus removal filter sample was filtered through a 0.1 micron pre-filter and then filtered with a 20 nm pore size virus removal filter membrane for 240 minutes. The filtrate volume was recorded, and the average filtration rate and the virus removal filter membrane load at the filtration end point were calculated. Sample 1: The cation collection liquid was prepared in the manner of Example 2. The cation collection liquid was frozen at -80°C for 5 to 7 days and then taken out and thawed in a 26°C water bath. It was diluted 1 to 1.5 times with 325mM acetic acid-sodium acetate buffer (pH5.0), and then filtered with a 0.22 micron filter membrane. The final sample concentration was 8.5g / L; Sample 2: The cation collection liquid was prepared in the manner of Example 2. The cation collection liquid was directly diluted 1 to 1.5 times with 325mM acetic acid-sodium acetate buffer (pH5.0), and then filtered with a 0.22 micron filter membrane. The final sample concentration was 7.3g / L;

[0068] The comparison of the average filtration rate and membrane loading capacity at the filtration end point of virus removal of different samples is shown in Table 4. Sample 1 was freeze-thawed and had a lower purity. Its average filtration rate and membrane loading capacity at the filtration end point were significantly lower than those of the sample that had not been freeze-thawed and had a higher purity.

[0069] Table 4 Comparison of average filtration rate and membrane loading at the filtration end point for virus removal of different samples

[0070]

Claims

1. A method for treating a purified intermediate of an antibody molecule, characterized in that: It includes: The purified intermediate is diluted with a buffer containing salt and / or amino acid, and the pH is adjusted to 5.5 to obtain a diluted sample; wherein: The buffer used for the dilution is a combination of 25 mM acetic acid-sodium acetate and 200 mM NaCl; or a combination of 40 mM acetic acid-sodium acetate and 200 mM arginine; the dilution multiple is 1 or more, and the final concentration of the salt and / or amino acid is 80-100 mM; The purified intermediate is a cationic collection solution obtained by eluting the antibody molecule; The buffer salt of the buffer solution is the same as that of the buffer solution used for elution; the buffer salt is acetic acid-sodium acetate; and the acetic acid-sodium acetate buffer used for elution does not contain salt and amino acids; The diluted samples were further subjected to the following steps: (i) filtering the diluted sample and storing it at -80°C; (ii) Thawing and filtering in a 26°C water bath to remove viruses; The filtration in steps (i) and (ii) uses a 0.22 micron filter; The antibody is an OX40 / PDL1 bispecific antibody, namely IBI327.

2. The processing method according to claim 1, characterized in that: The concentration of the antibody molecules in the diluted sample is below 8 g / L.

3. The treatment method according to claim 1, wherein the pH of the buffer used for elution is 5.0 to 5.4; And / or, the elution is gradient elution.